Leading Pediatric Expert Supports
Improvements in Child Health Products
October 24, 2006 - A presentation published
in a new volume of the Nestle Nutrition Workshop Series, “Protein
and Energy Requirements in Infancy and Childhood” describes
the health benefits of breast milk and also supports the addition
of two recombinant human breast milk proteins to child health and
nutrition products. The paper titled “Recombinant Human Milk
Proteins” was presented by Bo Lönnerdal, Ph.D., Department
of Nutrition, University of California, Davis at the 58th Nestle
Nutrition Workshop, Pediatric Program, Ho Chi Minh City, Vietnam,
November 2005.
This presentation emphasizes what numerous studies
on breast milk have conclusively demonstrated – breast-fed infants have
generally better health than formula-fed infants. Breast milk proteins “provide
amino acids, but also facilitate the absorption of nutrients, stimulate
growth and development of the intestine, modulate immune function
and aid in the digestion of other nutrients,” said Dr. Lönnerdal.
Ventria Bioscience produces two recombinant breast
milk proteins, Lactiva™ and Lysomin™ for use in medical foods and
child health and nutrition products. Both of these proteins are
found naturally in breast milk and have numerous beneficial effects
for children who are breastfeeding. “Ventria’s Lactiva™ and
Lysomin™ have been shown to have identical functional and
biological activity as their breast milk counterparts” said
Dr. Lönnerdal. And because Ventria has discovered a method
of making these proteins in an affordable system, the benefits
of these proteins have the potential to help millions of children
worldwide.
“Dr. Lönnerdal’s statements are consistent with
a recently completed child health study which demonstrated that
Ventria’s Lactiva and Lysomin, when added to standard oral
rehydration solution, helped to reduce the duration of acute diarrhea
in children by 30%, from 5.2 days to 3.7 days,” said Scott
Deeter, President and CEO, Ventria Bioscience. “We are very
pleased by the support from the pediatric medical community.”
For more information, see our website at Ventria Bioscience
http://www.ventria.com
Or contact:
Brandy Sargent, Corporate Communications
BSargent@Ventria.com
(916) 921-6148 ext. 27
Statements in this announcement other than historical data and
information constitute forward looking statements that involve
risks and uncertainties that could cause actual results to differ
materially from those stated or implied by such forward-looking
statements. Potential risks and uncertainties may include, but
are not limited to, recent changes in senior management, fluctuations
in operating results, market conditions and changes in technology
and increased competition.
|